US · COGT
Cogent Biosciences, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Waltham, MA 02140
- Website
- cogentbio.com
Price · as of 2025-12-31
$36.63
Market cap 6.31B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $16.52 | $15.86 | $7.25 | $0.00 | $0.00 |
| 2019 | $2.12 | $29.74 | $48,293.72 | $0.00 | $0.00 |
| 2020 | $8.18 | $25.25 | $12.66 | $0.00 | $364.84 |
| 2021 | $5.81 | $28.82 | |||
| 2022 | $11.66 | ||||
| 2023 | $6.59 | ||||
| 2024 | $7.01 | ||||
| 2025 | $38.89 |
AI valuation
Our deep-learning model estimates Cogent Biosciences, Inc.'s (COGT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $36.63
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| COGT | Cogent Biosciences, Inc. | $36.63 | 6.31B | — | — | — | — | -7.99 | 4.13 | — | -6.03 | -218.46 | 4.13 | 0.00% | — | — | -73.70% | 2714.02% | -51.99% | 0.40 | -108.87 | 14.23 | 14.08 | 0.18 | 366.00% | — | 2766.00% | -10.12% | -4.13 | 2165.58% | 0.00% | 0.00% | 0.00% | -5.94 | -7.45 | — | 3.37 |
| AGIO | Agios Pharmaceuticals, In… | $30.23 | 1.77B | -31% | +212% | — | — | -4.10 | 1.42 | 31.33 | -1.93 | — | 1.42 | 88.26% | -873.87% | -764.01% | -30.20% | -85.25% | -27.89% | 0.05 | — | 11.46 | 10.52 | 0.06 | -16117.00% | 4803.00% | -364.00% | -22.29% | -4.54 | -68.29% | 0.00% | 0.00% | 0.46% | -1.91 | -2.39 | 16.67 | 8.79 |
| DNLI | Denali Therapeutics Inc. | $21.18 | 3.31B | — | — | — | — | -7.19 | 3.63 | — | -5.73 | -46.19 | 3.63 | 0.00% | — | — | -45.69% | -177.80% | -40.69% | 0.03 | — | 9.16 | 8.82 | 0.35 | 1556.00% | — | 1609.00% | -11.46% | -4.20 | -135.14% | 0.00% | 0.00% | 1.26% | -5.13 | -6.75 | — | 13.60 |
| GLPG | Galapagos N.V. | $33.66 | 2.22B | +251% | +430,280% | +154% | +4,930% | 6.01 | 0.60 | 1.73 | -1.90 | 1.80 | 0.60 | 93.49% | 40.56% | 28.85% | 10.47% | 2205.83% | 8.51% | 0.00 | 164.04 | 20.15 | 19.95 | -0.14 | 33304.00% | 30348.00% | -4967.00% | -10.50% | -1.24 | -989.65% | 0.00% | 0.00% | 1.20% | -2.34 | 5.22 | -0.95 | 8.66 |
| IBRX | ImmunityBio, Inc. | $9.78 | 9.63B | +901% | -57% | — | — | — | -19.22 | 84.77 | -45.80 | — | -18.70 | 99.34% | -226.00% | -310.18% | 0.00% | -52123.97% | 0.00% | -1.76 | -2.28 | 5.10 | 4.62 | -3.53 | -3871.00% | 66831.00% | -2341.00% | -3.18% | -4.94 | -62105.09% | 0.00% | — | 0.00% | -39.99 | -33.58 | 90.38 | -5.49 |
| LQDA | Liquidia Corporation | $31.02 | 2.7B | -15% | +1,142% | — | -41% | -8.95 | 15.09 | 83.34 | -9.61 | -24.05 | 16.61 | 58.00% | -866.63% | -931.65% | -209.35% | -667.62% | -74.80% | 1.58 | -9.71 | 4.43 | 4.29 | 0.47 | 3719.00% | -1997.00% | 12955.00% | -8.43% | -2.24 | -541.45% | 0.00% | 0.00% | 1.71% | -9.17 | -11.31 | 79.48 | 0.24 |
| OCUL | Ocular Therapeutix, Inc. | $8.94 | 1.95B | +214% | -39% | — | +53% | -7.73 | 3.14 | 39.67 | -5.60 | -47.16 | 3.14 | 87.31% | -521.04% | -513.17% | -54.85% | 13699.49% | -42.01% | 0.12 | -22.82 | 15.39 | 15.11 | 2.63 | 1639.00% | -1867.00% | 5952.00% | -10.55% | -4.03 | 11004.21% | 0.00% | 0.00% | 16.58% | -5.18 | -6.45 | 26.99 | 6.07 |
| RCUS | Arcus Biosciences, Inc. | $20.37 | 2.05B | +8% | -43% | — | — | -7.28 | 4.07 | 10.41 | -5.04 | -152.47 | 4.07 | 95.95% | -156.28% | -142.91% | -63.26% | 112.87% | -30.84% | 0.16 | -48.25 | 4.36 | 4.25 | 0.37 | 478.00% | -426.00% | 17500.00% | -18.82% | -2.09 | 141.52% | 0.00% | 0.00% | 1.28% | -4.38 | -3.49 | 6.84 | 1.13 |
| RXRX | Recursion Pharmaceuticals… | $3.67 | 1.47B | +586% | +721% | — | — | -2.52 | 1.44 | 21.75 | -1.71 | — | 2.47 | -61.96% | -867.87% | -863.35% | -59.54% | -127.75% | -44.12% | 0.07 | -358.08 | 5.50 | 5.20 | 1.19 | -1479.00% | 2692.00% | 145.00% | -23.29% | -2.52 | -74.58% | 0.00% | 0.00% | 11.05% | -1.48 | -2.53 | 12.84 | 0.01 |
| VRDN | Viridian Therapeutics, In… | $29.38 | 2.39B | +11,973% | +7,221% | — | — | -7.49 | 3.55 | 36.21 | -5.16 | — | 3.55 | 98.36% | -512.91% | -483.57% | -49.16% | 573.89% | -41.73% | 0.07 | -73.44 | 12.65 | 12.37 | 0.48 | -1658.00% | 2335993.00% | 1892.00% | -10.79% | -3.91 | 437.27% | 0.00% | 0.00% | 3.24% | -4.79 | -6.29 | 24.58 | 6.44 |
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- CEO
- Andrew R. Robbins
- Employees
- 205
- Beta
- 0.47
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $36.63) − 1 = — (DCF, example).